DE602005022191D1 - Tricyclische verbindungen und deren verwendung als mglur1-antagonisten - Google Patents
Tricyclische verbindungen und deren verwendung als mglur1-antagonistenInfo
- Publication number
- DE602005022191D1 DE602005022191D1 DE602005022191T DE602005022191T DE602005022191D1 DE 602005022191 D1 DE602005022191 D1 DE 602005022191D1 DE 602005022191 T DE602005022191 T DE 602005022191T DE 602005022191 T DE602005022191 T DE 602005022191T DE 602005022191 D1 DE602005022191 D1 DE 602005022191D1
- Authority
- DE
- Germany
- Prior art keywords
- tricyclic compounds
- mglur1 antagonists
- mglur1
- antagonists
- tricyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101150076361 GRM1 gene Proteins 0.000 title 1
- 102100036834 Metabotropic glutamate receptor 1 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B57/00—Other synthetic dyes of known constitution
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57992004P | 2004-06-15 | 2004-06-15 | |
PCT/US2005/020972 WO2006002051A1 (en) | 2004-06-15 | 2005-06-14 | Tricyclic compounds and their use as mglur1 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005022191D1 true DE602005022191D1 (de) | 2010-08-19 |
Family
ID=35044971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005022191T Active DE602005022191D1 (de) | 2004-06-15 | 2005-06-14 | Tricyclische verbindungen und deren verwendung als mglur1-antagonisten |
Country Status (14)
Country | Link |
---|---|
US (2) | US7485648B2 (de) |
EP (1) | EP1765829B1 (de) |
JP (1) | JP2008502693A (de) |
CN (1) | CN101001862A (de) |
AR (1) | AR049300A1 (de) |
AT (1) | ATE473229T1 (de) |
CA (1) | CA2571012A1 (de) |
DE (1) | DE602005022191D1 (de) |
ES (1) | ES2348453T3 (de) |
HK (1) | HK1097269A1 (de) |
MX (1) | MXPA06014913A (de) |
PE (1) | PE20060526A1 (de) |
TW (1) | TWI292400B (de) |
WO (1) | WO2006002051A1 (de) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
WO2006081072A1 (en) * | 2005-01-24 | 2006-08-03 | Abbott Laboratories | Antagonists of the mglu receptor and uses thereof |
JP2009504755A (ja) * | 2005-08-19 | 2009-02-05 | シェーリング コーポレイション | 治療剤としての縮合三環式mGluR1アンタゴニスト |
JP2009508966A (ja) | 2005-09-23 | 2009-03-05 | シェーリング コーポレイション | 治療薬としての縮合四環性mGluR1アンタゴニスト |
EP1829879A1 (de) * | 2006-02-10 | 2007-09-05 | Cellzome (UK) Ltd. | Amino Pyrimidine Verbindungen zur Behandlung von entzündlichen Erkrankungen |
CL2007003444A1 (es) * | 2006-11-30 | 2008-06-27 | Genentech Inc | Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. |
DK2299821T3 (en) * | 2008-06-10 | 2016-02-15 | Abbvie Inc | Tricyclic compounds |
BRPI0909957A2 (pt) * | 2008-06-11 | 2016-04-19 | Genentech Inc | "composto, composição farmacêutica, método de inibir o crescimento anormal de células ou de tratar um distúrbio hiperproliferativo em um mamífero, método de tratamento do câncer em um mamífero" |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
CN108774237A (zh) | 2009-12-01 | 2018-11-09 | Abbvie 公司 | 新的三环化合物 |
US20110183938A1 (en) * | 2009-12-16 | 2011-07-28 | Genentech, Inc. | 1,7-diazacarbazoles and methods of use |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
JP2013518085A (ja) | 2010-02-01 | 2013-05-20 | ノバルティス アーゲー | CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体 |
ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
US8993779B2 (en) | 2010-08-12 | 2015-03-31 | Merck Sharp & Dohme Corp. | Positive allosteric modulators of MGLUR2 |
US9067948B2 (en) * | 2012-07-11 | 2015-06-30 | Nimbus Iris, Inc. | IRAK inhibitors and uses thereof |
KR101446680B1 (ko) | 2013-02-08 | 2014-10-07 | 한국과학기술연구원 | mGluR1 길항제로 작용하는 사이에노피리미디논 유도체 |
CN103265478B (zh) * | 2013-05-20 | 2015-09-30 | 中国人民解放军第二军医大学 | 巯基烟酸类化合物及其制备方法 |
CN104161757B (zh) * | 2013-05-20 | 2016-06-22 | 中国人民解放军军事医学科学院微生物流行病研究所 | 巯基烟酸类化合物的用途 |
US10035771B2 (en) | 2013-05-20 | 2018-07-31 | Institute Of Microbiology And Epidemiology, Academy Of Military Medical Sciences, Pr China | Mercaptonicotinic acid compound and preparation method and use thereof |
GB201401886D0 (en) | 2014-02-04 | 2014-03-19 | Lytix Biopharma As | Neurodegenerative therapies |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
CN116284011A (zh) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
JOP20180114B1 (ar) | 2016-06-22 | 2022-09-15 | Univ Vanderbilt | عوامل تعديل متباينة التجاسم موجبة من مستقبل الأسيتيل كولين المسكاريني m4 |
MA46899A (fr) | 2016-11-07 | 2021-04-14 | Univ Vanderbilt | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
WO2018085808A1 (en) | 2016-11-07 | 2018-05-11 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
BR112018013882A2 (pt) | 2016-11-07 | 2018-12-18 | Vanderbilt University | moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4 |
TW201930311A (zh) | 2017-12-05 | 2019-08-01 | 泛德比爾特大學 | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 |
WO2019113174A1 (en) | 2017-12-05 | 2019-06-13 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
AU2019205087B2 (en) * | 2018-01-05 | 2021-06-10 | Ac Immune Sa | 1, 3, 4, 5-tetrahydro-2H-pyrido(4,3-b)indole derivatives for the treatment, alleviation or prevention of disorders associated with Tau aggregates like Alzheimer's disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
AU1071301A (en) * | 1999-11-01 | 2001-05-14 | Eli Lilly And Company | Pharmaceutical compounds |
US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
WO2002062803A1 (fr) | 2001-02-08 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de thienopyrimidine |
WO2005076861A2 (en) * | 2004-02-04 | 2005-08-25 | University Of Virginia Patent Foundation | Compounds that inhibit hiv particle formation |
US7598259B2 (en) * | 2004-06-15 | 2009-10-06 | Schering Corporation | mGluR1 antagonists as therapeutic agents |
WO2006081072A1 (en) | 2005-01-24 | 2006-08-03 | Abbott Laboratories | Antagonists of the mglu receptor and uses thereof |
-
2005
- 2005-06-13 PE PE2005000672A patent/PE20060526A1/es not_active Application Discontinuation
- 2005-06-13 AR ARP050102395A patent/AR049300A1/es not_active Application Discontinuation
- 2005-06-14 DE DE602005022191T patent/DE602005022191D1/de active Active
- 2005-06-14 CA CA002571012A patent/CA2571012A1/en not_active Abandoned
- 2005-06-14 JP JP2007516647A patent/JP2008502693A/ja not_active Withdrawn
- 2005-06-14 AT AT05761566T patent/ATE473229T1/de not_active IP Right Cessation
- 2005-06-14 WO PCT/US2005/020972 patent/WO2006002051A1/en active Application Filing
- 2005-06-14 TW TW094119693A patent/TWI292400B/zh active
- 2005-06-14 US US11/152,535 patent/US7485648B2/en not_active Expired - Fee Related
- 2005-06-14 MX MXPA06014913A patent/MXPA06014913A/es active IP Right Grant
- 2005-06-14 EP EP05761566A patent/EP1765829B1/de active Active
- 2005-06-14 CN CNA2005800274208A patent/CN101001862A/zh active Pending
- 2005-06-14 ES ES05761566T patent/ES2348453T3/es active Active
-
2007
- 2007-04-27 HK HK07104505.3A patent/HK1097269A1/xx not_active IP Right Cessation
-
2008
- 2008-11-04 US US12/264,676 patent/US20090082336A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2008502693A (ja) | 2008-01-31 |
EP1765829A1 (de) | 2007-03-28 |
US20090082336A1 (en) | 2009-03-26 |
PE20060526A1 (es) | 2006-07-13 |
AR049300A1 (es) | 2006-07-12 |
CA2571012A1 (en) | 2006-01-05 |
US7485648B2 (en) | 2009-02-03 |
WO2006002051A1 (en) | 2006-01-05 |
HK1097269A1 (en) | 2007-06-22 |
CN101001862A (zh) | 2007-07-18 |
EP1765829B1 (de) | 2010-07-07 |
TWI292400B (en) | 2008-01-11 |
ATE473229T1 (de) | 2010-07-15 |
TW200609231A (en) | 2006-03-16 |
ES2348453T3 (es) | 2010-12-07 |
MXPA06014913A (es) | 2007-03-21 |
US20060009477A1 (en) | 2006-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE473229T1 (de) | Tricyclische verbindungen und deren verwendung als mglur1-antagonisten | |
DE602005023639D1 (de) | Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten | |
DE602005010961D1 (de) | Phenylcarbazole basierte Verbindungen und deren Verwendung als organische Elektroluminiszierende Vorrichtung | |
ATE471938T1 (de) | Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten | |
DE602005022116D1 (de) | 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren | |
DE602005025110D1 (de) | Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren | |
DE602005015699D1 (de) | Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren | |
ATE473214T1 (de) | 2-(4-oxo-4h-chinazolin-3-yl)acetamide und ihre verwendung als vasopressin-v3-antagonisten | |
DE602005022115D1 (de) | Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren | |
ATE440095T1 (de) | Benzimidazolderivate und ihre verwendung als aii rezeptor-antagonist | |
DE602005022169D1 (de) | Polymerisierbare verbindungen und verwendung davon | |
ATE511507T1 (de) | Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten | |
DE602006013878D1 (de) | Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel | |
ATE492545T1 (de) | Verbindungen und zusammensetzungen als proteinkinase-hemmer | |
ATE543825T1 (de) | Spiro-oxindolverbindungen und ihre verwendungen als therapeutische mittel | |
ATE378338T1 (de) | Pyrrolopyridinderivate und deren verwendung als crth2-antagonisten | |
DE602005011593D1 (de) | Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten | |
ATE440093T1 (de) | 1-alkinyl-2-aryloxyalkylamide und ihre verwendung als fungizide | |
ATE518872T1 (de) | Trizyklische verbindungen und deren verwendung als glucocorticoidrezeptormodulatoren | |
DK2783682T3 (da) | Farmaceutisk sammensætning omfattende pimobendan | |
ATE538130T1 (de) | Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten | |
ATE478059T1 (de) | Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten | |
ATE487707T1 (de) | (6-flu0r-benz0äl, 3üdioxolyl)-morpholin-4-yl- methanone und deren verwendung als cbl-liganden | |
ATE396185T1 (de) | Substituierte 4-alkyl- und 4- alkanoylpiperidinderivate und deren verwendung als neurokininantagonisten | |
DE602005009355D1 (de) | Gehinderte himbacinanaloga als thrombinrezeptorantagonisten |